- Home
- KOYN vs TENX Comparison
KOYN vs TENX Comparison
Compare KOYN & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOYN | TENX |
|---|---|---|
| Founded | 2024 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.7M | 317.8M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | KOYN | TENX |
|---|---|---|
| Price | $10.17 | $14.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 9.9K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.85 | $5.80 |
| 52 Week High | $10.17 | $19.40 |
Technical Indicators
Market Signals| Indicator | KOYN | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 60.77 | 46.84 |
| Support Level | $10.08 | $12.84 |
| Resistance Level | N/A | $16.35 |
| Average True Range (ATR) | 0.01 | 1.21 |
| MACD | 0.00 | -0.33 |
| Stochastic Oscillator | 85.71 | 4.81 |
Price Performance
Historical ComparisonAbout KOYN CSLM Digital Asset Acquisition Corp III Class A Ordinary Shares
CSLM Digital Asset Acquisition Corp III Ltd is a blank check company that acts to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.